Mersana Therapeutics (MRSN) Expected to Announce Quarterly Earnings on Wednesday

Mersana Therapeutics (NASDAQ:MRSN) is expected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $7.71 million for the quarter.

Mersana Therapeutics Stock Performance

Mersana Therapeutics stock opened at $0.53 on Monday. The stock has a 50-day simple moving average of $0.97 and a 200 day simple moving average of $1.60. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 12-month low of $0.49 and a 12-month high of $6.28. The stock has a market capitalization of $65.87 million, a price-to-earnings ratio of -0.87 and a beta of 1.40.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. William Blair assumed coverage on Mersana Therapeutics in a research report on Thursday, February 6th. They issued an “outperform” rating for the company. Wedbush restated an “outperform” rating and set a $4.00 target price (down from $7.00) on shares of Mersana Therapeutics in a research report on Friday, January 10th. Finally, Citigroup began coverage on Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mersana Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $5.57.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.